Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication

Area of Science:

• Hepatology
• Virology
• Public Health

Background:

• Hepatitis C virus (HCV) poses a significant global health challenge, with 170 million infected individuals.
• HCV is a primary cause of chronic hepatitis, cirrhosis, liver cancer, and liver transplantation.
• Hepatitis C virus genotype 6 (HCV-6) is geographically concentrated in South China and Southeast Asia, with diverse subtypes.

Purpose of the Study:

• To provide a comprehensive review of Hepatitis C virus genotype 6 (HCV-6).
• To detail the epidemiology, classification, diagnostic methods, and treatment options for HCV-6.
• To summarize current evidence on optimal treatment durations and emerging therapies for HCV-6.

Main Methods:

• Review of existing literature on HCV-6 epidemiology, classification, and diagnosis.
• Analysis of current treatment guidelines and clinical evidence for HCV-6.
• Discussion of diagnostic tools, including direct sequencing, phylogenetic analysis, and rapid genotyping tests like INNO-LiPA II.

Main Results:

• HCV-6 exhibits significant genetic diversity with 23 identified subtypes.
• Clinical manifestations of HCV-6 are similar to other HCV genotypes.
• Optimal treatment for HCV-6 with pegylated interferon/ribavirin is 48 weeks, potentially shortened to 24 weeks for select patients.
• Direct-acting antiviral agents show high response rates when combined with standard therapy.

Conclusions:

• HCV-6 requires specific consideration due to its genetic diversity and geographic distribution.
• Accurate diagnosis and subtype identification are crucial for effective management.
• Current treatment strategies involve interferon-based therapies, with promising advancements in direct-acting antivirals for improved patient outcomes.